Vincerx Pharma Inc (VINC)

$0.6824

-0.01

(-1.19%)

Market is closed - opens 7 PM, 21 May 2024

Insights on Vincerx Pharma Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 54.7% return, outperforming this stock by 111.0%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 226.3% return, outperforming this stock by 321.6%

Performance

  • $0.68
    $0.70
    $0.68
    downward going graph

    0.0%

    Downside

    Day's Volatility :2.86%

    Upside

    2.86%

    downward going graph
  • $0.61
    $9.37
    $0.68
    downward going graph

    10.29%

    Downside

    52 Weeks Volatility :93.49%

    Upside

    92.74%

    downward going graph

Returns

PeriodVincerx Pharma IncIndex (Russel 2000)
3 Months
-77.65%
0.0%
6 Months
-1.2%
0.0%
1 Year
-56.97%
0.0%
3 Years
-95.3%
-19.9%

Highlights

Market Capitalization
21.3M
Book Value
$0.52
Earnings Per Share (EPS)
-1.89
Wall Street Target Price
7.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-68.72%
Return On Equity TTM
-136.38%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-42.6M
Diluted Eps TTM
-1.89
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.28
EPS Estimate Next Year
-0.76
EPS Estimate Current Quarter
-0.23
EPS Estimate Next Quarter
-0.22

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Vincerx Pharma Inc(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 925.79%

Current $0.68
Target $7.00

Technicals Summary

Sell

Neutral

Buy

Vincerx Pharma Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Vincerx Pharma Inc
Vincerx Pharma Inc
-20.53%
-1.2%
-56.97%
-95.3%
-96.47%
Moderna, Inc.
Moderna, Inc.
27.23%
68.31%
4.86%
-19.93%
488.05%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
9.12%
22.54%
30.71%
91.4%
224.65%
Novo Nordisk A/s
Novo Nordisk A/s
5.29%
27.32%
54.69%
226.34%
458.15%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
11.32%
24.76%
30.96%
105.54%
168.64%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Vincerx Pharma Inc
Vincerx Pharma Inc
NA
NA
NA
-1.28
-1.36
-0.69
NA
0.52
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.04
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.57
28.57
1.46
44.2
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
46.03
46.03
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.58
28.58
0.53
17.11
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Vincerx Pharma Inc
Vincerx Pharma Inc
Buy
$21.3M
-96.47%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$50.8B
488.05%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$106.7B
224.65%
28.57
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$593.5B
458.15%
46.03
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$113.7B
168.64%
28.58
39.46%

Institutional Holdings

  • Goldman Sachs Group Inc

    14.53%
  • SAGE RHINO CAPITAL LLC

    7.24%
  • Long Focus Capital Management, LLC

    4.67%
  • Bank of America Corp

    4.60%
  • Rock Springs Capital Management LP

    3.79%
  • Kingdon Capital Management LLC

    3.27%

Company Information

vincerx is a clinical-stage life sciences company focused on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer.

Organization
Vincerx Pharma Inc
Employees
42
CEO
Dr. Ahmed M. Hamdy M.D.
Industry
Miscellaneous

FAQs